SOPHiA GENETICS ( (SOPH) ) just unveiled an update.
SOPHiA GENETICS reported its financial results for the fourth quarter and full year of 2024, showing a modest revenue growth of 4% year-over-year. The company achieved significant operational improvements, including an 11% reduction in operating loss and a record number of new customer acquisitions. Despite challenges in the BioPharma sector, SOPHiA GENETICS expanded its customer base and launched new products, positioning itself for accelerated growth in 2025. The company aims to achieve positive adjusted EBITDA by the second half of 2027, with a strong focus on operational excellence and market expansion.
More about SOPHiA GENETICS
SOPHiA GENETICS is a cloud-native software company specializing in data-driven medicine. It focuses on genomic analysis and provides solutions for cancer and rare disease cases, with a significant presence in the U.S. and international markets.
YTD Price Performance: 15.05%
Average Trading Volume: 75,884
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $239.9M
For an in-depth examination of SOPH stock, go to TipRanks’ Stock Analysis page.